Simulect (basiliximab) / Novartis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

7 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Simulect (basiliximab) / Novartis
NCT01469390: Pharmacodynamics, Efficacy, Safety of Basiliximab 40 or 80 mg Combined With CsA or Everolimus, in Low Risk de Novo Renal Transplant Recipients

Not yet recruiting
2
50
Europe
Basiliximab, Simulect
Novartis Pharmaceuticals
Renal Transplantation
04/13
 
NCT02464878: Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

Completed
2
2
US
Alpha 1-Antitrypsin, Glassia, Islet Transplantation, Thymoglobulin, Antithymocyte Globulin, Basiliximab, Etanercept, Enbrel
Massachusetts General Hospital, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Iowa
Kidney Transplant, Type 1 Diabetes
11/22
12/22
NCT04337593: Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

Not yet recruiting
2
20
NA
Basiliximab, anti-CD25 antibody, Pegaspargase
Beijing Tongren Hospital
Extranodal NK/T-cell Lymphoma
05/22
12/22
FWCSWG-IL-2, NCT05013034: Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients

Not yet recruiting
2
300
NA
Basiliximab Injection, Simulect, Placebo
Fort Worth Clinical Sciences Working Group, TCU and UNTHSC School of Medicine
SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection, Cytokine Storm
10/22
12/22
NCT06480630: Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases

Not yet recruiting
2
39
RoW
Basiliximab
Anhui Provincial Hospital
Acute Graft Versus Host Disease, Malignant Hematologic Neoplasm
06/26
06/27
NCT04871607: Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Recruiting
2
33
US
Basiliximab, SDZ-CHI-621, Simulect, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Genetically Engineered Hematopoietic Stem Progenitor Cells, Genetically Engineered HSPCs, Recombinant Granulocyte Colony-Stimulating Factor, Recombinant Colony-Stimulating Factor 3, rhG-CSF, Yttrium Y 90 Basiliximab, 90Y Basiliximab, Yttrium Y 90-DOTA-Basiliximab
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
10/27
10/27
ACTRN12605000802606: SHIRT (Salvage Hodgkins Immunoradiotherapy)

Recruiting
1/2
10
 
South Metropolitan Area Health Service WA, Physician Sponsored
Lymphoproliferative Malignancies (Relapsed or Refractory)
 
 

Download Options